Nasus Pharma to Present Data on Intranasal Epinephrine Powder at AAAAI 2026

The data highlights the powder's potential for superior nasal deposition and stability.

Published on Feb. 18, 2026

Got story updates? Submit your updates here. ›

Nasus Pharma, a clinical-stage pharmaceutical company, announced that it will present data on its investigational intranasal epinephrine powder formulation, NS002, at the AAAAI 2026 Annual Meeting in Philadelphia. The data is expected to showcase NS002's potential for superior epinephrine absorption and robust formulation stability, making it a unique and potentially superior option for the treatment of anaphylaxis.

Why it matters

Anaphylaxis is a severe and potentially life-threatening allergic reaction, and the rapid delivery of epinephrine is crucial in emergency situations. Nasus Pharma's intranasal powder formulation aims to deliver epinephrine more quickly than traditional autoinjectors, which could provide a significant advantage in treating anaphylaxis.

The details

The data being presented at AAAAI 2026 will highlight that the nasal powder formulation of NS002 has significantly higher deposition in the nasal cavity compared to liquid nasal sprays, which could lead to enhanced blood absorption. Additionally, the company will present data showing that the FMXIN002 Epinephrine Intranasal Powder Spray is stable throughout 3 freeze-thaw cycles.

  • The AAAAI 2026 Annual Meeting will take place in Philadelphia, PA, USA, from February 27 to March 2, 2026.
  • The data on NS002 will be presented on March 1, 2026, at 9:45-10:45 AM.

The players

Nasus Pharma Ltd.

A clinical-stage pharmaceutical company focused on the development of innovative intranasal products, including the investigational intranasal epinephrine powder formulation NS002.

Dan Teleman

Chief Executive Officer of Nasus Pharma.

Tair Lapidot, PhD

VP of R&D and Clinical Development at Nasus Pharma, and the corresponding author for the presentations.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to share data highlighting NS002's potential for superior epinephrine absorption and robust formulation stability.”

— Dan Teleman, Chief Executive Officer (biospace.com)

“Designed as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology.”

— Dan Teleman, Chief Executive Officer (biospace.com)

“We believe NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis, where seconds truly matter.”

— Dan Teleman, Chief Executive Officer (biospace.com)

What’s next

The upcoming data presentation at AAAAI 2026 will provide more details on the potential advantages of Nasus Pharma's intranasal epinephrine powder formulation, NS002, compared to traditional liquid nasal sprays.

The takeaway

Nasus Pharma's intranasal epinephrine powder formulation, NS002, aims to deliver epinephrine more rapidly in emergency situations, which could provide a significant advantage in the treatment of anaphylaxis. The upcoming data presentation at AAAAI 2026 will shed more light on the potential benefits of this innovative approach.